|
Home | Medical-Newswire.Com:
|
(Medical-NewsWire.com, June 15, 2016 ) Publisher's market research analyst predicts the global gastric cancer drugs market to grow rapidly at a CAGR of approximately 8% during the forecast period. The presence of huge unmet needs in the market is expected to result in this market's healthy growth during the forecast period. The presence of this high-unmet medical need will lead to an increased R&D of safe and effective drugs, which in turn will spur market growth during the estimated period.
The recent increase in the prevalence of gastric cancer due to lifestyle changes is expected to drive market growth. The sedentary lifestyle, excessive smoking, increased consumption of alcohol, and a rise in obesity are envisaged to result in the increased incidence of gastric cancer.
For more information about this report: http://www.reportsweb.com/global-gastric-cancer-drugs-market-2016-2020 .
Geographical segmentation and analysis of the gastric cancer drugs market
- Americas
- APAC
- Europe
In this market study, analysts have estimated the APAC region to account for the highest market share during the forecast period. Much of this region's growth can be attributed to the increasing demand for better healthcare infrastructure, which results in its massive market share of nearly 48% during the forecast period.
Competitive landscape and key vendors
The global gastric cancer drugs market is growing rapidly owing to the high proportion of individuals with gastric cancer and the presence of a strong drug pipeline. To gain traction in this market, the vendors are manufacturing and marketing gastric cancer drugs that exhibit a high safety and efficacy profile, this helps the vendors to gain a competitive edge over their peers.
Request Sample Copy at http://www.reportsweb.com/inquiry&RW0001202225/sample .
The top vendors in the market are -
- Hoffmann-La Roche
- Eli-lilly
- Sanofi
- Otsuka Holdings
Other prominent vendors in the market include Novartis, Amgen, Boston Biomedical, AROG Pharmaceuticals, ARIAD Pharmaceuticals, Roche, Merck, Eli Lilly, AB Science, Galena Biopharma, AstraZeneca, Taiho Oncology, Samumed, Ipsen Biopharmaceuticals, Eddingpharm, Tekmira Pharmaceuticals, Bristol-Myers Squibb, Gilead Sciences, ASLAN Pharmaceuticals, Five Prime, Array Biopharma, BIND Therapeutics, Boehringer Ingelheim, Daiichi-Sankyo, Bayer HealthCare, and Celgene.
Make an enquiry: http://www.reportsweb.com/inquiry&RW0001202225/buying .
ReportsWeb.com
Priya Sisodia
+1-646-491-9876
sales@reportsweb.com
Source: EmailWire.Com 
Source: EmailWire.com
|
|
|
|
